CA2157902A1 - Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates - Google Patents

Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates

Info

Publication number
CA2157902A1
CA2157902A1 CA002157902A CA2157902A CA2157902A1 CA 2157902 A1 CA2157902 A1 CA 2157902A1 CA 002157902 A CA002157902 A CA 002157902A CA 2157902 A CA2157902 A CA 2157902A CA 2157902 A1 CA2157902 A1 CA 2157902A1
Authority
CA
Canada
Prior art keywords
enantiomeric
residue
precursor
reagent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002157902A
Other languages
English (en)
Inventor
Christopher Douglas Valiant Black
Robert Allen Snow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2157902A1 publication Critical patent/CA2157902A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CA002157902A 1993-03-10 1994-03-10 Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates Abandoned CA2157902A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3308393A 1993-03-10 1993-03-10
US033083 1993-03-10
PCT/US1994/002610 WO1994020523A1 (fr) 1993-03-10 1994-03-10 Ciblage de tumeur au moyen de conjugues oligonucleotidiques l-enantiomeres d'immunoreactifs et de radionucleides chelates

Publications (1)

Publication Number Publication Date
CA2157902A1 true CA2157902A1 (fr) 1994-09-15

Family

ID=21868470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002157902A Abandoned CA2157902A1 (fr) 1993-03-10 1994-03-10 Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates

Country Status (5)

Country Link
EP (1) EP0691981A1 (fr)
JP (1) JPH08512019A (fr)
AU (1) AU6402594A (fr)
CA (1) CA2157902A1 (fr)
WO (1) WO1994020523A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021957A1 (fr) * 1992-05-07 1993-11-11 Sterling Winthrop Inc. Complexants et immunoreactifs de ciblage
EP2415776B1 (fr) 1998-08-10 2016-05-25 Novartis AG Bêta-L-2'-désoxy-nucléosides pour le traitement de l'hépatite B
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE60140863D1 (de) * 2001-06-10 2010-02-04 Noxxon Pharma Ag Verwendung von L-Polynukleotiden zur diagnostischen Bilderzeugung
EP1288309A1 (fr) * 2001-08-30 2003-03-05 Noxxon Pharma AG Procédé pour marquer les L-acides nucléiques
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
EP1306382A1 (fr) * 2001-10-26 2003-05-02 Noxxon Pharma AG L-acides nucléiques modifiés
US7629456B2 (en) * 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2004024095A2 (fr) 2002-09-13 2004-03-25 Idenix (Cayman) Limited ss-L-2'-DESOXYNUCLEOSIDES POUR LE TRAITEMENT DE SOUCHES RESISTANTES DU VHB, ET THERAPIES COMBINEES ASSOCIEES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US5158880A (en) * 1988-09-23 1992-10-27 E. I. Du Pont De Nemours And Company Process for preparing solid perfluorocarbon polymer supports having attached perfluorocarbon-substituted ligand or binder
US5367080A (en) * 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods

Also Published As

Publication number Publication date
EP0691981A1 (fr) 1996-01-17
WO1994020523A1 (fr) 1994-09-15
JPH08512019A (ja) 1996-12-17
AU6402594A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
US5733523A (en) Targeted delivery of a therapeutic entity using complementary oligonucleotides
CA2150477A1 (fr) Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates
CA2157902A1 (fr) Ciblage de tumeurs a l'aide de conjugues d'oligonucleotide l-enantiomeres d'immunoreactifs et de radionucleides chelates
JP3143506B2 (ja) 治療用物質の標的送達用医薬組成物
JP2009197024A (ja) 金属複合体及びオリゴヌクレオチドから作られた接合体、該接合体を含む薬剤、放射線診断におけるそれらの使用並びにそれらの製造のための方法
US5746997A (en) Radiohalogenation of oligonucleotides via trialkylstannylaryl conjugates
US20020077306A1 (en) Conjugates made of metal complexes and oligonucleotides, agents containing the conjugates, their use in radiodiagnosis as well as process for their production
EP0675737A1 (fr) Reactifs a reactivite immunologique utilisant la dihydrofolate reductase
EP0613379B1 (fr) Composes therapeutiques
CA2164518A1 (fr) Agents immunoreactifs utilisant la monoamine-oxydase
US7713528B1 (en) Method for in vivo delivery of active compounds using reagent conjugate
WO1997033626A1 (fr) Nouveaux chelateurs et compositions preparees a l'aide de ceux-ci
CA2154896A1 (fr) Agents immunoreactifs utilisant des heterodimeres
AU2036099A (en) Conjugates made of metal complexes and oligonucleotides

Legal Events

Date Code Title Description
FZDE Discontinued